Vincent Angotti Buys 213,310 Shares of Talphera (NASDAQ:TLPH) Stock

Talphera, Inc. (NASDAQ:TLPH) CEO Vincent Angotti bought 213,310 shares of the stock in a transaction dated Friday, March 13th. The shares were purchased at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the completion of the transaction, the chief executive officer directly owned 800,705 shares of the company’s stock, valued at $472,415.95. This trade represents a 36.31% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Talphera Stock Down 3.0%

Shares of TLPH opened at $0.77 on Friday. The business’s fifty day moving average is $0.87 and its 200 day moving average is $1.05. Talphera, Inc. has a 12-month low of $0.38 and a 12-month high of $1.57. The stock has a market cap of $38.67 million, a P/E ratio of -2.09 and a beta of 0.47.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. On average, analysts expect that Talphera, Inc. will post -0.64 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Group One Trading LLC increased its position in shares of Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after purchasing an additional 29,500 shares during the last quarter. Virtu Financial LLC bought a new position in Talphera during the third quarter valued at about $29,000. Mariner LLC grew its position in Talphera by 132.0% during the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after buying an additional 33,000 shares during the period. Persistent Asset Partners Ltd purchased a new stake in Talphera during the fourth quarter worth about $42,000. Finally, Dauntless Investment Group LLC purchased a new stake in Talphera during the third quarter worth about $89,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.